The market for inhaled nitric oxide experienced significant growth in recent years. In 2019, its size was valued at an impressive $634.4 million. However, this is just the beginning of its upward trajectory. With a projected compound annual growth rate (CAGR) of 8.1%, the market is estimated to reach a staggering $1,180.98 million by 2027. This exponential growth demonstrates the increasing demand and potential for inhaled nitric oxide in various applications. As the market continues to expand, it opens up new opportunities for innovation and advancement in this field.
Get Sample PDF Report with Graphs and Figures Here: www.alliedmarketresearch.com/request-sample/3020
Inhaled nitric oxide (iNO) has proven to be clinically efficient in its ability to dilate blood vessels and relax muscle tension, resulting in improved oxygen absorption in the body. This gas is typically administered through the nose or mouth, in conjunction with a breathing machine (ventilator).
iNO is widely recognized as a potent and selective pulmonary vasodilator, meaning it specifically targets and widens the blood vessels in the lungs without affecting systemic vascular tone. Its therapeutic application was initially described in the 1990s, and it has since become a crucial treatment option for newborn infants with respiratory failure caused by persistent pulmonary hypertension (PPHN).
The primary benefit of iNO therapy lies in its ability to enhance oxygenation in infants suffering from PPHN. Due to its selective pulmonary vasodilator effects, iNO therapy is particularly important for term newborns experiencing hypoxemic respiratory failure attributed to PPHN.
The United States Food and Drug Administration (FDA) granted approval for iNO usage as a medical gas in 1999. It is indicated for the treatment of hypoxic respiratory failure in term and late preterm neonates, specifically those exhibiting clinical or echocardiographic evidence of pulmonary hypertension. However, there is still ongoing discussion and no consensus regarding the application of iNO therapy for the treatment of PPHN in term and late preterm neonates.
Key Market Players
1. BOC HEALTHCARE
2. BELLEROPHON THERAPEUTICS
3. BEYOND AIR
4. HALMA PLC
5. LINDE PLC (PRAXAIR
6. VERO BIOTECH LLC
7. MALLINCKRODT PLC
8. NOVOTERIS
9. AIR LIQUIDE S.A.
10. NU-MED PLUS
The inhaled nitric oxide market can be segmented based on its applications and regions. Here are some highlights of the market report:
By Application:
Neonatal Respiratory Treatment: Inhaled nitric oxide is extensively used in the treatment of respiratory failure in neonates, particularly those with persistent pulmonary hypertension. It helps dilate the pulmonary blood vessels, improving oxygenation and reducing the need for extracorporeal membrane oxygenation (ECMO) therapy.
Chronic Obstructive Pulmonary Disease (COPD): Inhaled nitric oxide is being studied and utilized as a potential treatment option for COPD. It has shown promise in reducing pulmonary artery pressure and improving pulmonary function in patients with COPD.
Acute Respiratory Distress Syndrome (ARDS): ARDS is a severe condition characterized by lung inflammation and respiratory failure. Inhaled nitric oxide has been investigated as a therapy to improve oxygenation and reduce pulmonary hypertension in ARDS patients.
Others: In addition to neonatal respiratory treatment, COPD, and ARDS, inhaled nitric oxide may have potential applications in other respiratory conditions and diseases. Ongoing research is exploring its efficacy in pulmonary hypertension, pulmonary fibrosis, and other respiratory disorders.
By Region:
North America: This region includes the United States, Canada, and Mexico. North America is expected to be a significant market for inhaled nitric oxide, driven by advancements in healthcare infrastructure, increasing awareness of respiratory diseases, and rising demand for neonatal respiratory treatments.
Europe: European countries such as Germany, France, the United Kingdom, Italy, and others are part of this region. Europe is likely to witness substantial growth in the inhaled nitric oxide market, fueled by the presence of leading pharmaceutical companies, research institutions, and a high prevalence of respiratory diseases.
Asia-Pacific: Japan, Australia, and other countries in the Asia-Pacific region are expected to experience a growing demand for inhaled nitric oxide. Factors such as a large patient population, improving healthcare facilities, and rising investments in medical research and development contribute to the market growth in this region.
Rest of World: This category includes regions beyond North America, Europe, and Asia-Pacific. The inhaled nitric oxide market in these areas will be influenced by factors such as healthcare infrastructure development, increasing awareness about respiratory diseases, and advancements in treatment options.
Purchase the Report: www.alliedmarketresearch.com/inhaled-nitric-oxide-market/purchase-options
